Patent Strengthens Nexalin’s Intellectual Property Portfolio and Highlights the Potential of DIFS™ Technology in Addressing Substance Use Disorders, Including Opioids,…
NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small-molecule…
NKGen explores the use of troculeucel as a potential treatment option for post-stroke patients.SANTA ANA, Calif., March 03, 2025 (GLOBE…
TORONTO, March 03, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a…
Robust, Consistent Phase 3 Data and Real-World Evidence Outcomes Support ANX005 as Potential First Targeted Therapy for GBS; Pre-BLA Meeting…
Top-line data for REFOCUS-ALZ, the second Phase 3 study of simufilam in Alzheimer’s disease, expected late first-quarter/early second-quarter 2025License agreement…
BURLINGTON, Mass., March 03, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (Neuphoria or Company), ”), a clinical-stage biotechnology…
AI-Driven Insights to Be Integrated with Life Imaging FLA's Full-Body CT Scan Services Through Their Upcoming 200 Location Expansion DENVER…
Noom + HRTRx blends Noom’s proven behavior change program with HRT medication to achieve whole-person healthThe new offering builds on…
HALO™ Clarity Devices Successfully Shipped for First Phase of Clinical TrialsHOUSTON, TX, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology,…